α₁‐antitrypsin in acute anterior uveitis and rheumatic diseases

Abstract

To test the pathogenetic role of the phenotype MZ of alpha 1-antitrypsin/alpha 1-protease inhibitor (PI) in acute anterior uveitis (AAU) and in different rheumatic diseases we examined 360 unrelated patients including 93 with AAU alone, 24 patients with AAU and ankylosing spondylitis (AS), 21 patients with AAU and Reiter's disease (RD), 26 patients with AAU, AS, and RD 54 patients with AS alone, 16 patients with RD alone, 115 patients with rheumatoid arthritis (RA) alone, and 11 patients with psoriatic arthritis (PA) alone. Of the 164 AAU patients, 80 had a single attack, and 84 had repeated episodes. There were neither significant differences between different groups of the patients and 120 healthy controls nor between patients with AAU alone and patients with AAU and AS or RD in the frequencies of the PI phenotypes tested. The results indicate that the PI MZ type is not closely associated with AAU, AS, RD, RA and PA and that it does not play any role in determining whether AAU shows a pattern of a single attack or repeated episodes, and whether AAU occurs alone or together with AS or RD.

Recent Advances in the Research and Development of Alpha-1 Proteinase Inhibitor for Therapeutic Use

“…If further clinical studies support the safety and efficacy of an aerosolized 1 -PI, and it is approved for treatment of cystic fibrosis, the demand for therapeutic  1 -PI preparations could be significantly increased. Dowd et al, 1995;Esnault, 1997;Griffith et al, 1996Panniculitis Chowdhury et al, 2002Gross et al, 2009;Kjus et al, 2002;Smith et al, 1987;Valverde et al, 2008Fibromyalgia Ablin et al, 2009Blanco et al, 2004;Blanco et al, 2010Asthma Blanco et al, 2008Blanco et al, 2011;Eden et al, 1997Pancreatitis Rabassa et al, 1995Needlham & Stockley, 2004Renal Szönyi et al, 2006Ting et., 2008Diabetes Kalis et al, 2010Lisowska-Myjak et al, 2006;Cancer Li et al, 2011;Lindor et al, 2010;Topic et al, 2011Rheumatoid arthritis Grimstein et al, 2010Grimstein et al, 2011Atherosclerosis Stakisaitis et al, 2001Talmud et al, 2003; Acute anterior uveitis Fearnley et al, 1988;Saari et al, 1986 Chronic rhinosinusitis Kilty et al, 2008Kilty et al, , 2010Maune et al, 1995 (Cantin et al, 2002b). According to their data, the site-specific conjugation with either 20 or 40 kD PEG at Cys 232 of nonglycosylated r- 1 -PI (human) results in an active inhibitor with extended in vivo stability.…”